Endothelial cell-specific molecule-1 (endocan) is an immunoinflammatory marker linked to endothelial activation and dysfunction. We investigated the relationship between obstructive coronary artery disease (CAD), microvascular angina (MVA), and plasma levels of endocan. We included 53 healthy individuals as controls, 40 MVA patients, and 120 patients with obstructive CAD. The severity of CAD was assessed by the Gensini and SYNergy between percutaneous coronary intervention with TAXUS and Cardiac Surgery (SYNTAX) scores. Endocan levels were 382.7 (313.8-470.2) pg/mL in patients with obstructive CAD; 324.3 (277.1-460.7) pg/mL in MVA group, and 268.0 (226.4-336.5) pg/mL (P < .001) in controls. Endocan levels in obstructive CAD and MVA groups were similar but both were significantly higher than for the control group (P < .001 and P = .002, respectively). In subgroup analysis, similar to the hypertensive subgroup results, endocan was still an independent predictor of presence of obstructive CAD in normotensives (odds ratio = 1.005, 95% confidence interval = 1.001-1.010, P = .024). There was also an independent positive correlation between endocan levels and SYNTAX score both in the hypertensives (β = 0.414, t = 3.21, P = .002) and in the normotensives (β = .301, t = 2.23, P = .031). In conclusion, endocan could be a common predictor of the endothelium-dependent inflammatory processes, rather than related with specific risk factors.
LaneHASmithJCDaviesJS. Noninvasive assessment of preclinical atherosclerosis. Vasc Health Risk Manag. 2006;2(1):19–30.
2.
VermaSBuchananMRAndersonTJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108(17):2054–2059.
3.
BechardDScherpereelAHammadH. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167(6):3099–3106.
4.
GrigoriuBDDepontieuFScherpereelA. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 2006;12(15):4575–4582.
5.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243(1):339–343.
6.
BrandesRP. Endothelial dysfunction and hypertension. Hypertension. 2014;64(5):924–928.
7.
HoffJADaviglusMLChomkaEVKrainikAJSevrukovAKondosGT. Conventional coronary artery disease risk factors and coronary artery calcium detected by electron beam tomography in 30,908 healthy individuals. Ann Epidemiol. 2003;13(3):163–169.
8.
XiongCZhaoZWChenZY. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association With Coronary Artery Disease in Patients With Hypertension. J Investig Med. 2015;63(7):867–870.
9.
WangXSYangWLuoTWangJMJingYY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19(3):124–127.
RadicoFCicchittiVZimarinoMDe CaterinaR. Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests. JACC Cardiovasc Interv. 2014;7(5):453–463.
12.
OngPAthanasiadisABorgulyaGMahrholdtHKaskiJCSechtemU. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol. 2012;59(7):655–662.
13.
HalcoxJPSchenkeWHZalosG. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106(6):653–658.
14.
PepineCJAndersonRDSharafBL. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55(25):2825–2832.
15.
CreaFCamiciPGBairey MerzCN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35(17):1101–1111.
16.
TousoulisDDaviesGJAsimakopoulosG. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol. 2001;24(4):301–304.
17.
Cosin-SalesJPizziCBrownSKaskiJC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol. 2003;41(9):1468–1474.
18.
SYNTAX score calculator. Version 2.1. SYNTAX working group. Web site. http://www.syntaxscore.com. Updated March 14, 2011. Accessed August 20, 2015.
19.
GensiniGG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.
20.
TadzicRMihaljMVcevAEnnenJTadzicADrenjancevicI. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res. 2013;37(2-3):103–115.
21.
LassallePMoletSJaninA. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458–20464.
22.
Ait-OufellaHTalebSMallatZTedguiA. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(5):969–979.
23.
MaunoVHannuKEskoK. Proinflammation and hypertension: a population-based study. Mediators Inflamm. 2008;2008:619704.
24.
CelikTBaltaSKaramanM. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015;24(1):55–60.
25.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behcet disease. J Am Acad Dermatol. 2014;70(2):291–296.
26.
BaltaIBaltaSDemirkolS. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066–1070.
27.
BaltaSOzturkC. Endocan, Obstructive Sleep Apnea, and Vascular Risk. Angiology. 2016;67(4):305–306.
28.
PetersenJWPepineCJ. Microvascular coronary dysfunction and ischemic heart disease: where are we in 2014?Trends Cardiovasc Med. 2015;25(2):98–103.
29.
OngPSivanathanRBorgulyaG. Obesity, inflammation and brachial artery flow-mediated dilatation: therapeutic targets in patients with microvascular angina (cardiac syndrome X). Cardiovasc Drugs Ther. 2012;26(3):239–244.
30.
Recio-MayoralARimoldiOECamiciPGKaskiJC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging. 2013;6(6):660–667.
31.
RasmiYRaeisiSSeyyed MohammadzadMH. Association of inflammation and cytotoxin-associated gene a positive strains of helicobacter pylori in cardiac syndrome x. Helicobacter. 2012;17(2):116–120.
32.
TondiPSantoliquidoADi GiorgioA. Endothelial dysfunction as assessed by flow-mediated dilation in patients with cardiac syndrome X: role of inflammation. Eur Rev Med Pharmacol Sci. 2011;15(9):1074–1077.
33.
Arroyo-EspligueroRMollichelliNAvanzasP. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J. 2003;24(22):2006–2011.
34.
GulatiMCooper-DeHoffRMMcClureC. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med. 2009;169(9):843–850.
35.
BaltaSMikhailidisDPDemirkolS. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–777.
36.
Abu El-AsrarAMNawazMIDe HertoghG. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Curr Eye Res. 2015;40(3):321–331.
37.
ArmanYAkpinarTSKoseM. Effect of Glycemic regulation on endocan levels in patients with diabetes: a preliminary study. [Published May 12, 2015] Angiology. 2015.
38.
KoseMEmetSAkpinarTS. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology. 2015;66(8):727–731.
39.
YilmazMISiriopolDSaglamM. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86(6):1213–1220.
40.
MenonPKocherOAirdW. Endothelial cell specific molecule-1 (ESM-1), a novel secreted proteoglycan stimulates vascular smooth muscle cell proliferation and migration. Circulation. 2011;124:a15455.
